美国疾控中心称:心衰死亡率近两年再次升高

2016-01-05 Mechront 译 MedSci原创

美国疾病控制与预防中心(CDC)的一个新报告称,尽管与心衰相关死亡人数有超过10年的时间在稳步下降,但这一比例又开始在不断的增加。报告显示,年龄校正后的心衰相关死亡率在2000年为105.4/100,000,在2012年下降到为81.4/100,000(P<0.05),但是2014年的数据却是小幅上升达84.0/100,000。还有一些并不令人惊讶的发现:2014年所有年龄段,男性死亡率高于

美国疾病控制与预防中心(CDC)的一个新报告称,尽管与心衰相关死亡人数有超过10年的时间在稳步下降,但这一比例又开始在不断的增加。


报告显示,年龄校正后的心衰相关死亡率在2000年为105.4/100,000,在2012年下降到为81.4/100,000(P<0.05),但是2014年的数据却是小幅上升达84.0/100,000。

还有一些并不令人惊讶的发现:2014年所有年龄段,男性死亡率高于女性;黑人死亡率(91.5/100,000)高于白人(87.3/100,000)和西班牙籍(53.3/100,000)。

除此之外该报告也发布了一些好的方面:住院期间心衰相关的死亡比例从2000年的42.6%,下降到2014年的30%;45岁以上CHD患者心衰死亡率从2000年的34.9%下降到2014年的23.9%。

CDC国家卫生统计中心Hanyu Ni博士称:“2014年与2000年相比,导致心衰死亡的根本原因,更可能是除CHD之外的其他心血管疾病或非心血管疾病(癌症、糖尿病、慢性下呼吸道疾病和肾脏疾病)。死于中缺血性心脏病所占比例更小,了解死亡原因对心衰患者的管理至关重要。”

对于这份报告,研究者检查了来自全国重要统计数据的“死亡档案”的数据,均符合报告结果。心衰相关死亡不论男女,从2000到2012年处于下降趋势,但其之后开始上升。到目前为止,2014岁死亡率最高的年龄组为84岁以上人群(男性 2842.8/100,000;女性2333.5/100,000);接着是75-84岁人群(男性 720/100,000;女性504.7/100,000)。

从2000年到2012年,年龄校正后心衰相关死亡率黑人中下降20%,白人中下降22%;但从2012年到2014年两组人群死亡率均上升了4%。不过西班牙籍呈现稳步下降,2000年到2014年下降27%。

随着院内心衰死亡率的下降,养老院等长期护理机构的死亡率也有所下降,从2000年的30.1%下降到2014年的26.7%。不过居住地心衰相关死亡率从18.3%增加到27.6%,门诊或临终关怀部门死亡率也从9%增加到15.7%。

最后研究者称:“2014年45岁及以上死于心衰的人群病因中CHD占23.9%,其他心血管疾病占41.2%,非心血管疾病占34.9%。”

原始出处:

Ni H, Xu J. Recent trends in heart failure-related mortality: United States, 2000–2014. NCHS data brief, 231. Hyattsville, MD: National Center for Health Statistics. 2015. Report

CDC: Heart-Failure–Related Mortality Rate Climbs After Decade-Long Decrease

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=54358, encodeId=ac385435892, content=哦,, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Fri Jan 08 01:26:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54359, encodeId=db105435955, content=哦,, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Fri Jan 08 01:26:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54360, encodeId=5d6354360e7, content=哦,, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Fri Jan 08 01:26:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405298, encodeId=3077140529811, content=<a href='/topic/show?id=3f67e0632c0' target=_blank style='color:#2F92EE;'>#疾控中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70632, encryptionId=3f67e0632c0, topicName=疾控中心)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/0AD7956C8522FF8EF9A242DC5569528A/100, createdBy=d51a2536255, createdName=zutt, createdTime=Thu Jan 07 04:09:00 CST 2016, time=2016-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52312, encodeId=0c2952312f4, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Wed Jan 06 01:02:00 CST 2016, time=2016-01-06, status=1, ipAttribution=)]
    2016-01-08 medsic

    哦,

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=54358, encodeId=ac385435892, content=哦,, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Fri Jan 08 01:26:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54359, encodeId=db105435955, content=哦,, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Fri Jan 08 01:26:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54360, encodeId=5d6354360e7, content=哦,, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Fri Jan 08 01:26:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405298, encodeId=3077140529811, content=<a href='/topic/show?id=3f67e0632c0' target=_blank style='color:#2F92EE;'>#疾控中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70632, encryptionId=3f67e0632c0, topicName=疾控中心)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/0AD7956C8522FF8EF9A242DC5569528A/100, createdBy=d51a2536255, createdName=zutt, createdTime=Thu Jan 07 04:09:00 CST 2016, time=2016-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52312, encodeId=0c2952312f4, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Wed Jan 06 01:02:00 CST 2016, time=2016-01-06, status=1, ipAttribution=)]
    2016-01-08 medsic

    哦,

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=54358, encodeId=ac385435892, content=哦,, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Fri Jan 08 01:26:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54359, encodeId=db105435955, content=哦,, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Fri Jan 08 01:26:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54360, encodeId=5d6354360e7, content=哦,, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Fri Jan 08 01:26:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405298, encodeId=3077140529811, content=<a href='/topic/show?id=3f67e0632c0' target=_blank style='color:#2F92EE;'>#疾控中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70632, encryptionId=3f67e0632c0, topicName=疾控中心)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/0AD7956C8522FF8EF9A242DC5569528A/100, createdBy=d51a2536255, createdName=zutt, createdTime=Thu Jan 07 04:09:00 CST 2016, time=2016-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52312, encodeId=0c2952312f4, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Wed Jan 06 01:02:00 CST 2016, time=2016-01-06, status=1, ipAttribution=)]
    2016-01-08 medsic

    哦,

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=54358, encodeId=ac385435892, content=哦,, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Fri Jan 08 01:26:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54359, encodeId=db105435955, content=哦,, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Fri Jan 08 01:26:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54360, encodeId=5d6354360e7, content=哦,, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Fri Jan 08 01:26:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405298, encodeId=3077140529811, content=<a href='/topic/show?id=3f67e0632c0' target=_blank style='color:#2F92EE;'>#疾控中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70632, encryptionId=3f67e0632c0, topicName=疾控中心)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/0AD7956C8522FF8EF9A242DC5569528A/100, createdBy=d51a2536255, createdName=zutt, createdTime=Thu Jan 07 04:09:00 CST 2016, time=2016-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52312, encodeId=0c2952312f4, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Wed Jan 06 01:02:00 CST 2016, time=2016-01-06, status=1, ipAttribution=)]
    2016-01-07 zutt
  5. [GetPortalCommentsPageByObjectIdResponse(id=54358, encodeId=ac385435892, content=哦,, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Fri Jan 08 01:26:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54359, encodeId=db105435955, content=哦,, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Fri Jan 08 01:26:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54360, encodeId=5d6354360e7, content=哦,, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Fri Jan 08 01:26:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405298, encodeId=3077140529811, content=<a href='/topic/show?id=3f67e0632c0' target=_blank style='color:#2F92EE;'>#疾控中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70632, encryptionId=3f67e0632c0, topicName=疾控中心)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/0AD7956C8522FF8EF9A242DC5569528A/100, createdBy=d51a2536255, createdName=zutt, createdTime=Thu Jan 07 04:09:00 CST 2016, time=2016-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52312, encodeId=0c2952312f4, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Wed Jan 06 01:02:00 CST 2016, time=2016-01-06, status=1, ipAttribution=)]
    2016-01-06 zhuzhuba1

    0

相关资讯

Lancet Haematology:心衰患者应提前预防静脉血栓栓塞

静脉血栓栓塞症是一个重大的全球性健康问题,往往是继发于其他临床情况。许多研究已经调查静脉血栓栓塞和心脏衰竭之间的关联,但产生了不一致的结果。该研究的目是量化心衰患者入院后静脉血栓栓塞的绝对和相对危险度(RR)。研究人员还评估了患者在不同环境下的静脉血栓栓塞率。在这个系统评价和荟萃分析中,研究人员检索了心衰患者入院治疗后静脉血栓栓塞症的风险研究。研究人员检索了1955年1月1日和2015年3月31日

Nucl Acids Res:为何会出现心脏肥大?

在心脏发育的早期阶段有负责细胞生长分化的特定基因,今后生活中这些基因被重新激活会导致心肌异常增厚。Silke Rickert-Sperling教授已经能够识别潜在的分子机制。发表在Nucleic Acids Research上的研究是第一次描述一个特定的蛋白质在促进一种常见心脏病中的作用。心肌的异常增厚导致心脏肥大,以持续应对增加的心脏压力如高血压。当心脏细胞大小增加,称之为“肥厚性”(心脏壁增厚

JACC:中度至重度CKD心衰患者中,接受带有除颤器的CRT治疗可显著降低心衰入院和死亡的概率

中度至重度慢性肾脏病(CKD)患者在心脏再同步化治疗(CRT)的临床试验比较少。本研究旨在评估CRT-符合条件的中度至重度CKD患者接受带有除颤器的CRT(CRT-D)治疗 vs 单独植入式心脏复律除颤器(ICD)治疗的效果比较。研究人员对10946例CRT-符合条件的患者(射血分数<35%,QRS>120 ms,纽约心脏协会功能分级III / IV)且CKD在国家心血管数据注册(NC

JAMA Intern Med:一种综合认知行为疗法可有效缓解心衰患者的抑郁症状

抑郁和自我护理不足是心衰(HF)患者常见的问题,是增加其住院和死亡风险的相互关联问题。该研究的目的是确定一种综合认知行为疗法(CBT)干预对于治疗抑郁症和HF自我护理的疗效。该随机临床试验采用单盲结果进行评估。符合条件的患者在2010年1月4日和6月28日2013年之间被招募进入美国圣路易斯华盛顿大学医学中心。主要数据分析是在2015年2月进行的分析。参加者为158名门诊病人,纽约心脏协会分类为I

Circulation:野生型转甲状腺素蛋白淀粉样变性引起的心衰研究

由于野生型转甲状腺素淀粉样变性(ATTRwt)引起心脏衰竭是老龄化人群发病率和死亡率的一个被低估的原因。这项研究的目的是检查疾病的特性和在一项大的ATTRwt队列研究的表征结果。在过去的20多年中,121例ATTRwt患者被纳入一个前瞻性观察研究中。招募时患者的中位年龄为75.6岁(范围62.6-87.8);97%的患者是高加索人。中位生存期,通过活检诊断测量,为46.69个月(95%Cl,41.

JACC:首次发现睡眠和心衰相关基因食欲素受体2,或可开启心衰治疗的新方向!

斯坦福大学医学院的研究者发现了一个基因,当正常工作时可减少心衰风险且改善治疗预后,成为了开发新药的可能目标。研究者首次发现,当该基因编码蛋白质发生突变形式会引起嗜睡症!据估计美国心衰患者花费400亿美元/年,目前治疗心衰的研发过程中存在瓶颈,未找到与心衰绝对相关的基因,现有治疗不同人的反应差异很大。Ashley希望该基因的发现有望打开心衰治疗的大门。Perez称“心衰患者接受现有治疗,有的人疗效非